Campaigners and manufacturers today issued a High Court challenge against the decision by the National Institute of Clinical Excellence to bar drug treatments to patients with early and late-stage Alzheimer's Disease.
NICE guidance issued last November barred prescription of donepezil, rivastigmine and galantamine for early-stage Alzheimer's and memantine for late-stage disease.
Application for a judicial review was lodged this week by the Alzheimer's Society charity, following an application last week by Eisai and Pfizer, manufactuers of donepezil.
Neil Hunt, chief executive of the Alzheimer's Society, said. 'This is a fatally flawed decision and we are left with no choice but to challenge it in court.'